YJBM: ItA such a pleasure to have this opportunity to speak with you. So what was it like getting the Nobel Prize? JS: Well, it was amazing. I gather that some people expect to win the Nobel Prize, but this was not the case for me at all. I'm very pleased that it has come because it's recognition for work on this little one-millimeter nematode worm that Sydney Brenner's group started studying back in the 1960s. A lot of people worked on it, and I feel great that I'm a representative of that community and have brought the field to this recognition. The reason for the Nobel prize this year is because the third member of the trio, Bob Horvitz, has really driven this along at MIT and has acquired a large part of the genetic pathway, that is the series of genes that control programmed cell death. A number of these genes are found in the human body as well. And when they go awry they can cause some medical conditions that are troubling, for example, some sorts of neurodegenerative diseases are caused by these cell death pathways being invoked inappropriately. So you see by learning about the genes in the worm, we're now moving that into applications and eventually medical cures in the human we hope.
YJBM: And so in scientific terms was it just a small stepfrom working on the worm and its genetic structure to the human? JS: I was was working on the cells of the worm in the 1970s, and I wasn't terribly concemed with the genes. When I finished the cell lineages, it was a little bit ofa resting moment for me; I wasn't sure what to do. What I noticed was that lots ofpeople were finding genes in the sense offinding defective worms; they knew there was something wrong, and they had to pin it down. It was a very tedious step to actually find the particular bit of all the DNA. The worm DNA has 100 million bases, or letters, in its length so it's really a needle in a haystack job to find a few thousand letters that are responsible for the gene of interest and then to pin down exactly what's gone wrong. It seemed to me that what one should do is to work on the whole DNA and really get it mapped out and organized as a way to make it much easier for people. We started doing this in the early 1980s.
And this really was the beginning, our efforts and others' parallel efforts, which led to this new field of genomics, which has made such a difference in biology. It JS: Oh yes, those long, tatty pieces ofpaper spread out across the wall at the back of the room. What it was is that was called the map. That was not the sequence, not the 100 million letters, but that was an assembly of about 20,000 segments of the DNA, we split it up into segments. We figured out how they overlapped. That was the beginning of the utility of it. The point of that was that we stored all of these segments; they were growing in bacteria in our lab and we could store them away in our freezer and when somebody wanted a particular segment, we would just send it out to them. The interesting thing is we stored all of those segments or clones away in the beginning ofthe 1980s and they're still being sent out every week, in increasing numbers, actually, they're still useful. And so even though we now have the whole sequence, we know where the letters are, and people still find these segments useful. They can actually use them. They can manipulate them and inject them into worms and work on the genes that way. It's curious, I never would have imagined that something I did would have lasted for so long.
YJBM: So who jbrmed the initial consortium to decipher the human genome? It was quite a collaboration, with participantsfiom many countriesw and different research centers.
JS: It began in the United States, and it arose in part from our efforts with the worm. There were several key meetings that were held in the U.S. The first ofthese was organized by [Robert] Sinsheimer at Santa Cruz. It was Charles De Lisi at DOE (Department of Energy)b who really set it offand announced that DOE would make a serious effort towards doing a similarjob for the human genome culminating in sequencing it. Then towards the end of the 1980s, the NIH (National Institutes of Health) had come firmly into he picture, and Jim Watson was appointed to head it up.
The thing formally came into being in 1990 with a view to deciphering the human genome in not more than 15 years, though I think everybody hoped it would go a bit faster. In fact, the worm was very much caught up in this project because the idea was to sequence the code of not only the human genome but a number of these other organisms. It was very obvious that this would help not only in developing technology but in understanding, because you could do experiments on them. So that's how the human genome project came into being. The other thing was that Jim Watson felt it should very much be international. The human genome is something that is shared by all of humankind, and so it seemed absolutely right and natural that it should be done in some sort of communal way. JS: It does come out to personalities, although that's partly the way we deal with things in our society. I've had to learn to cope with it. It's the same with all these disputes with presidents and everything, you always focus it into one person. In fact I think it's more correct to say that it's a political dispute really, and you've got certain front people who do most of the talking. And the political dispute was quite simply over whether this particular project should or could appropriately be done in a for-profit way. What Celera proposed to do was to sequence the human genome and keep the data in a database and charge people for access. And after all this is something that is commonly done, one sells goods and services, why not?
The position of the consortium that formed the human genome project was that it should be released freely. There are certain things we accept in our society as being infrastructure that we do not charge for. We don't charge each other for the air we breathe, although we may charge for the delivery of air or water, but we don't think these things should be owned at source. We think that these are common goods and human rights. We possibly feel more strongly about some things here in Europe. Land for example, especially in Scandinavia, is considered a common good where you can roam freely. It's this kind of dispute.
I feel that the human genome is so basic and so common to us all. It's not something that anybody has invented. We all have our individual variations ofcourse, but the background reference sequence is common to all of us. So it seemed to me and to my colleagues self-evident that this was the right way to go. It has some very practical consequences as well.
One thing, in particular, that affects all scientists is that if you lock things up in a private database in the fashion that was proposed by Celera for the human genome then some individuals who don't have money can't get access, which is bad. And apart from that you forbid people to talk to each other about it because they must be forbidden to redistribute the information. On the other hand, when you want to deal with these 3,000 million letters, it's not so easy to actually do any research on it. This is the science that we call bioinformatics, the computing associated with the understanding of the genome. It's not so easy to do the computing and to disseminate the results by speaking or publication without actually disseminating the sequence as well. And so it's extremely inefficient and inhibitory to research to have a very large body of basic information like the human genome locked up in a private database.
And so I think that on that principle alone it really was important, and it's very good that we got it out into the public, and the battle is over now; it's not a problem anymore. That's the reason I think that we should make sure this communal data is available.
Something that increasingly concerns me, and the human genome is just an example, is that when we do privatize goods in this way we also block them out from the greater number ofpeople in the world who are too poor to participate, and so I think we have to be very careful about our good just doing only that but that the reason for large numbers of people in the world being impoverished is not rnning world trade correctly and that we're running it in such a way which is increasing the wealth disparity rather than narrowing it, and so they've realized that it's right that they should take an active role in arguing about exactly how international trade relations should be conducted.
I came in at the moment when people were started to get agitated about the socalled TRIPPS Agreement, the Trade-Related Intellectual Property Rights Agreement, which was set up by the world trade organization back in 1995, but is now beginning to be implemented because there was a delay after the initial agreement. What we've all started to realize is that the TRIPPS Agreement is going to make impoverished countries even more impoverished because it's imposing Western, that is to say American and European, patent law on countries who are going to get no benefit from it whatever. It's actually going to increase our wealth at their expense. This seems to me to be to be absolutely wrong, and I think OxFam is absolutely right. I've been extremely impressed with their researchers, and the same is true with MSF. These people are playing an invaluable role in uncovering the practicalities as well as the rights and wrongs of world trade in a way that is independent ofgovernment and ofcorporate power. This is an unbiased view, I think I've learned a lot from them, and I intend to go on doing so. YJBM: What is it about this whole project and about understanding the human in this way that frightens so many people? A CNN/Time magazine poll taken two yeacrs ago showed that 46 percent ofthe respondents expected harmful results from the endeavor Forty percent expected benefits, but 41 percent said that the project is morally wrong. And we've heard recent rumors about an Italian doctor who has supposedly cloned an embryo who is to be born sometime next year JS: I'm pretty certain that would be morally wrong if it's true, but I'm pretty certain that this story isn't correct. But if it is correct, then it would be extremely dangerous. We know from animal cloning that most of the animals die or are born defective in some way. The idea of producing humans this way in the current state of human development would be criminal. I hope it isn't true although this certainly might be done in the future. But except for the cases of certain types of infertility, I don't think there's any point in cloning humans. It's far better to produce new humans with the random recombination. We've got so many possibilities for our genes, and on the whole it's more fun for the parents to produce a new kid rather than something that's absolutely identical to one or the other of them.
In general, I tend to relate the unease to the belief by some people that scientists have agendas. Again I would relate it back to the excessive use of the profit motive. When you finance research with venture capital, the person who has put the money in naturally wants to get a return as soon as Under these circumstances, it's no surprise that people are uneasy because they feel they're not being told the full story all of the time. I think it's extremely important in terms ofthese leading edge kinds of things that really are affecting people's health and welfare that we have independent experts who report in a way that doesn't have any kind of agenda. We're trying that in this country. I sit on something called "The Human Genetics Commission," which is free ofany controls. We don't have that bias in any way, and we're free to investigate. And I think we need to have plenty of these sorts of people around who can exercise independent judgements in order to make the system work. Collins estimated that it cost between 50 and 100 million dollars just to locate that particular gene. So we don't have that anymore; we've got the whole genome, and locating the particular genes on it is a much cheaper and faster operation.
You might also look at the way that people's particular variations might influence the drugs they should take. For example, some people are unusually susceptible to general anesthesia because they have a particular genetic modification; so by measuring these sorts of things, one can improve treatment for patients. We don't know exactly how far that's going to go. Some people say that it will go very far, and some people say the actual testing will be too expensive, and it won't be used a lot. I expect that it's going to be used a lot, because I believe that testing is going to become very inexpensive indeed.
I think that most people are excited by the possibilities of getting cures. People talk a lot about gene therapy, for example, which is quite a long way down the line. That's the process of delivering working genes to people who for hereditary or other reasons have a gene that's not working properly. And that's really hard because you have to deliver it and get the gene working in the right place.
One sort ofcure that I think is going to be enhanced in short order (by short I mean a decade or two) is cancer treatment. The reason for that is that we can investigate and find exactly what the changes are in particular tumor types that cause them to continue growing uncontrollably, eventually killing the patient. By having those targets, one will first of all be able to diagnose accurately, but in this case one will probably be able to move to cure because you're trying to get something to kill the tumor rather than bring in a healthy gene. That's a relatively easy matter, and I think that delivery methods will be brought in within the next decade or so. So I think we are going to see big changes in cancer treatment as a result. Beyond all of that, everything, all of medicine is affected, and people are going to be ingenious in using this new information in various ways.
YJBM: So Iguess that goes along with the question with which I want tofinish, which is one you pose yourself in the book, "Where does all of this achievementdraft and finished -stand in the overall scheme ofthings? Is it a BIG IDEA orjust an episode?" JS: What I want to say there is that we are in the middle of a really big era of change of understanding, which I would roughly define as molecular biology, in the sense that it subsumes most of biology in some sense. This is true not just for humans, of course, but for plant scientists and everybody. It is quite incredible to be dealing with the molecules of life. And it began around the time that DNA was discovered 50 years ago. What we say in the book is that the sequencing of the human genome is a splendid thing because it's sort of obviously iconic for us to have our own code. You can walk around with it on a CD ifyou want [laughs] and say, "Here we are, here're the instructions for making a human being." YJBM: We could get into some privacy issue here too. JS: Yes, that's right. But it's not meaningful except in terms of the understanding what's going to come, and so people should feel that it's really an exciting thing. It's like unwrapping a Christmas present that is a kit, and you have to figure out how to build the kit.
YJBM: So you've retired as the head of the Sanger (entre. What is your scientific research these days? JS: All the way along, I've been working on the nematode, and we're still working on tidying up little bits of its genome. I've also been spending lots of time writing this book and with the things rising out of the book. After what to me was the quite shocking episode of the attempt to privatize the human genome, I've become quite politicized and become quite concerned with the quite broader aspects that we've been discussing right now. I don't know exactly where it's going to go. I don't ask where I'm going, I just like to move forward to whatever interests me at the time. To be honest, this business of setting world trade to rights is most important. If I can help OxFam and any of the others in any way to do that, then I would be more than delighted.
